PDL BioPharma makes unsolicited bid for Neos Therapeutics

27 October 2017

PDL BioPharma (Nasdaq: PDLI) has submitted an unsolicited proposal to acquire fellow US drugmaker Neos Therapeutics (Nasdaq: NEOS) for $10.25 per share in cash.

This all-cash transaction represents a premium of 40% to the closing price of Neos shares on October 25, 2017 and a premium of 41% to Neos' share price prior to PDL's initial proposal on June 23, which Neos promptly rejected. The PDL proposal is not subject to any financing conditions.

With 28.08 million shares outstanding, the bid would imply a deal value of $287.8 million. Neos share rose 9.6% pre-market, prior to trading being halted. PDL stock was 5.47% lower at $3.03 in mid-morning trading Thursday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK